loader from loading.io

Dexcom’s Jake Leach on a new CGM for type 2, updates on G6, G7 and more!

Diabetes Connections | Type 1 Diabetes

Release Date: 02/13/2024

In the News...  Ingredients linked to T2D, genetic T1D research, new SGLT-2 guidelines and more! show art In the News... Ingredients linked to T2D, genetic T1D research, new SGLT-2 guidelines and more!

Diabetes Connections | Type 1 Diabetes

It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study links emulsifiers, a common ingrediant, to type 2 diabetes, reserachers map out the pancreas in a new way that's already yielding new information, new guidliens about using GLP-1s and SGLT-2 medications with exisiting oral meds, genetic T1D studies and more!  Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and...

info_outline
“How can we continue to move T1D to the background?” Medtronic’s Dr. Jennifer McVean show art “How can we continue to move T1D to the background?” Medtronic’s Dr. Jennifer McVean

Diabetes Connections | Type 1 Diabetes

This week, catching up with Medtronic’s Senior Director of Global Medical Affairs Dr. Jennifer McVean. It’s been one year since the 780G was approved in the US, what does the device – and its seven-day infusion set – look like in the real world. Plus, we have a big discussion about the future of type 1 diabetes – Dr. McVean has lead some significant trials – she lives with type 1 and has some big ideas about changes she’d like to see. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.   Find out...

info_outline
Meet the newest insulin pump: all about “twiist” with Sequel CEO Alan Lotvin show art Meet the newest insulin pump: all about “twiist” with Sequel CEO Alan Lotvin

Diabetes Connections | Type 1 Diabetes

This week, the newest pump coming to the market is called the twiist. It’s a very different shape – circular with a top half that twists off – with very different software – Tidepool Loop. The company behind this pump – they’re called Sequel - wants to be different as well, hoping to offer solutions to bigger issue than basal and bolus rates. It’s very ambitious and we have a wide ranging conversation about it all with Sequel’s CEO Alan Lotvin This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our...

info_outline
In the News... Dexcom-to-watch update, Wegovy studies, night time hypo research and more! show art In the News... Dexcom-to-watch update, Wegovy studies, night time hypo research and more!

Diabetes Connections | Type 1 Diabetes

It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom launches direct-to-watch with the G7 in the UK and Ireland, more studies looking at heart benefits with Wegovy and diabetes, a new T1D study investigating an injectable to prevent overnight hypoglycemia, lobbying for Levimir, a ChatGPT diabetes diagnosis and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and the show...

info_outline
The FDA took down this teen’s free bolus calculator. He needs your help to bring it back. show art The FDA took down this teen’s free bolus calculator. He needs your help to bring it back.

Diabetes Connections | Type 1 Diabetes

There used to be a lot of bolus calculators in the app store, maybe you’ve used one and haven’t updated it in a while. Don’t try now.. it’s likely been pulled. Apple and the FDA are cracking down on this types of tools – no unreasonable, right? But surely there are more coming.. how hard can it be to create a simple insulin bolus calculator that’s FDA approved, easy to find, easy to use, free, and doesn’t require you buy anything else? Turns out, it’s pretty darn hard. We’re talking about that today with the inventor of such an app with an interesting story – he’s still...

info_outline
Diabetes Technology: Expectation vs Reality with Dr. Stephen Ponder show art Diabetes Technology: Expectation vs Reality with Dr. Stephen Ponder

Diabetes Connections | Type 1 Diabetes

Diabetes technology is getting better and better. We have automated insulin systems that link pumps and CGMs, and smart insulin pens that have precise calculations and reminders. It’s been quite the evolution over the past few years! But outcomes – time in range, A1Cs, aren’t exactly where experts thought they might be. I’m talking to Dr. Stephen Ponder about why that is, how a social media post he shared about this caused a strong reaction, and what does work for better long term outcomes. This podcast is not intended as medical advice. If you have those kinds of questions, please...

info_outline
In the News... diabetes drug pricing, vial shortage, pump using Tidepool Loop cleared, insulin cows and more! show art In the News... diabetes drug pricing, vial shortage, pump using Tidepool Loop cleared, insulin cows and more!

Diabetes Connections | Type 1 Diabetes

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: a new study shows that drugs like Ozempic can be produced for just a few dollars, we upate the insulin vial shortage Lilly announced, a new pump has been FDA cleared, a genetically modified cow can product human insulin, and more! Transcript and links below Find out more about  Please visit our Sponsors & Partners - they help make the show possible! Learn more about   from extreme temperatures Learn more about  Drive  The best way to keep up...

info_outline
Answering your questions about Tandem’s new Mobi pump (and more) with Director of Product Marketing Ben Mar show art Answering your questions about Tandem’s new Mobi pump (and more) with Director of Product Marketing Ben Mar

Diabetes Connections | Type 1 Diabetes

Approved last year, Tandem’s Mobi is now widely available. We’re getting an update from Ben Mar, Director of Product Marketing, on the features of the Mobi that make this tiny pump different and we look ahead to what Tandem is working on next. Ben also answers your questions about everything from algorithm updates, international access, and much more This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about ...

info_outline
"It needs to be easier" - DIY pioneer Dana Lewis turns her attention to exercise and T1D

Diabetes Connections | Type 1 Diabetes

This week, one of the pioneers of the DIY movement is turning her attention to exercise. Dana Lewis is partnering with other researchers to create a tool to help you make better and easier decisions around whatever workout you choose. There’s a lot of variability here – big difference between say, weight lifting and long distance running – so this is no easy task. Dana will explain the tools they’re using, the big goals here, and we get to catch up about what she’s using these days to manage her life with T1D which now includes ultramarathoning. This podcast is not intended as...

info_outline
In the News... ATTD updates, new CGMs, drops for diabetes eye disease, scholarships and more! show art In the News... ATTD updates, new CGMs, drops for diabetes eye disease, scholarships and more!

Diabetes Connections | Type 1 Diabetes

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars. Transcript and links below Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures Learn more about Drive The best way to keep up with Stacey and...

info_outline
 
More Episodes

This week, we get an update from Dexcom. Chief Operating Officer Jake Leach talks about their soon to be launched CGM for people with type 2. It's called Stelo and it's front of the FDA right now.

We also answer a lot of your questions about G6, G7, interoperability, connectivity and what's next.

Some information on Stelo: https://diatribe.org/new-dexcom-cgm-people-type-2-diabetes-not-using-insulin

Find out more about Moms' Night Out 

Please visit our Sponsors & Partners - they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com)

Omnipod - Simplify Life

Learn about Dexcom 

Edgepark Medical Supplies

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here's where to find us:

Facebook (Group)

Facebook (Page)

Instagram

Twitter

Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 

Reach out with questions or comments: [email protected]

Episode summary (AI generated)

A new CGM product for people with type 2 diabetes.
Stacey Simms and Jake Leach discuss a new CGM product for people with type 2 diabetes, currently under FDA review.
Stello extends sensor wear to 15 days while maintaining accuracy and reliability for CGM users, regardless of insulin titration.
Stello aims to help people with diabetes understand how food impacts their glucose levels through a simple and user-friendly CGM device.

CGM for type 2 diabetes and payer coverage.
Jake Leach explains how the new CGM product will notify users of high glucose levels without alerting them to take insulin, providing valuable insights into food and diet impact on glucose levels.
Stacey Simms seeks more detail on the product and its potential for long-term use, expressing interest in education and training for users to fully understand and benefit from the technology.
Stacey Simms asks Jake Leach about the continuous use of CGMs, and Jake explains that the product is designed to be engaging and provide value continuously, with users learning and improving their diabetes management over time.
Jake also mentions that the company is working with payers to expand coverage for CGMs beyond Medicare, as it can be a challenge for people without insulin use.

CGM access, naming, and interoperability.
Stello is a cache pay product starting off affordable and competitive, with potential for reimbursement as evidence of benefits grows.
Jake Leach: Excited about new brand for Dexcom, with different design for new population, but still with expected performance reliability.
Jake Leach: G6 and G7 interoperability is a focus, with Omni pod integration and launch timing controlled by Dexcom.

G7 features and enhancements.
Jake Leach: Enhancements made to Bluetooth connectivity on G7 device, now available across channels and geographies.
Jake Leach discusses the company's focus on improving sensor reliability and user satisfaction through ongoing software development and user feedback.
The company prioritizes features based on user feedback and releases them in a timely manner, with a dedicated team working on the Apple Watch feature.

Dexcom's CGM technology and its potential for more widespread access.
Jake Leach and Stacey Simms discuss the evolution of G7, including its smaller size and reduced environmental footprint.
The company is working on a direct-to-watch submission and has validated alerts and alarms on the watch platform.
Dexcom aims to provide best CGM for users' pump systems, partnering with multiple companies globally.
Jake Leach is passionate about expanding access to CGM technology for people with diabetes worldwide.